Evolus Earnings Call Transcripts
Fiscal Year 2026
-
The meeting confirmed quorum, presented three proposals, and all were approved by shareholders. No questions were raised during the Q&A, and the meeting was conducted virtually with proper notice.
-
The company has evolved into a diversified aesthetics platform, expanding internationally and leveraging digital efficiencies for scalable growth. Product innovation, especially in HA injectables, and strong clinic partnerships drive market share gains. GLP-1 trends and a robust pipeline support long-term growth and profitability.
-
Q1 results showed 7% revenue growth, positive Adjusted EBITDA, and strong Jeuveau performance. Guidance for 2026 and long-term outlook remain unchanged, with double-digit revenue growth and margin expansion expected. Tariff risks are being proactively managed.
-
Mid-teens market share and double-digit growth were achieved in 2025, with international expansion and a new HA filler, Evolysse, strengthening the portfolio. The company expects continued growth, stable pricing, and profitability in 2026, with Sculpt poised as a key future driver.
-
Toxin market recovery began in late 2023, with filler recovery lagging but showing positive signs, especially in Europe. Product differentiation, portfolio bundling, and a robust loyalty program are driving growth, with 2026 revenue guidance at $327M-$337M and international expansion underway.
Fiscal Year 2025
-
Delivered 12% revenue growth in 2025 and achieved Q4 profitability despite a rare market decline. Guidance for 2026 targets 10–13% revenue growth, stable margins, and sustained profitability, with new product launches and international expansion supporting future growth.
-
Strong growth continues with Jeuveau and the rapid launch of Evolysse, supported by a robust financial position and expanding international presence. Market headwinds are being addressed through product differentiation, portfolio bundling, and innovation, with profitability targeted for Q4 2025 and a major portfolio expansion in 2026.
-
Q3 revenue rose 13% year-over-year to $69M, driven by Jeuveau and a strong Evolysse launch. Gross margin was 66.5%, and non-GAAP operating loss improved to $3.1M. 2025 guidance was reiterated, with profitability targeted for Q4 2025 and sustainable annual profits from 2026.
-
Second quarter revenue grew 4% year-over-year, driven by Evolysse's strong launch and international expansion, despite Jeuveau's first-ever decline amid a challenging U.S. market. Cost structure was optimized, guidance was reset, and profitability is targeted for 2026.
-
Q1 revenue grew 15.5% to $68.5M, driven by market share gains and a strong Jeuveau performance, while Evolysse launched with robust early adoption. 2025 guidance of $345M–$355M revenue and profitability was reaffirmed, supported by favorable debt refinancing and disciplined capital management.
-
Evolus is launching Evolysse, a differentiated hyaluronic acid filler, in Q2, leveraging a unique cold cross-linking process and targeted marketing to expand its portfolio. Financial guidance remains strong, with profitability achieved ahead of schedule and a focus on premium market positioning.
-
Management highlighted robust growth, with new product Evolysse expected to drive further gains and differentiation through innovation and targeted marketing. Long-term guidance projects at least $700 million in revenue by 2028, with strong operating leverage and disciplined international expansion.
-
Performance beauty strategy and innovative products drive strong growth, with a 14% toxin market share and new launches like Evolysse targeting weight loss patients. 2025 revenue is guided at $345–$355 million, with international expansion and a robust pipeline supporting long-term targets.
Fiscal Year 2024
-
Achieved full-year profitability in 2024, driven by 32% revenue growth and market share gains. FDA approval of new HA gels expands the addressable market, with 2025 revenue guidance of $345–$355 million and continued operating leverage expected.
-
Aesthetics-focused company is growing rapidly with a differentiated cash-pay model, expanding internationally, and launching innovative dermal fillers. Digital engagement and loyalty programs drive high customer retention and growth. 2028 guidance targets $700M+ revenue, with strong operating leverage and profitability expected.
-
Q3 net revenue grew 22% year-over-year to $61.1 million, with strong U.S. market share gains and the launch of Estyme in Europe. 2024 revenue guidance was narrowed to $260–$266 million, and profitability is targeted for Q4 2024 and full year 2025.
-
The company is redefining aesthetics as performance beauty, leveraging digital innovation, a cash pay model, and a strong brand to achieve rapid growth and high market share. With new filler launches, robust clinical data, and a scalable digital platform, it targets $700M+ revenue and 20%+ margins by 2028, supported by strong financials and multiple growth drivers.
-
Performance beauty company has grown Jeuveau to 13% U.S. market share, expanded its addressable market with a new filler line, and achieved early profitability. Focused on millennials and international growth, it expects stable margins and no major capital needs through 2028.
-
Profitability was achieved ahead of schedule in Q2 2024, with 36% revenue growth and Jeuveau's market share rising to 13%. Full-year revenue guidance was raised, and the company is preparing for a major filler launch in 2025 while expanding internationally.